Literature DB >> 12749605

Analysis of sex, age and disease factors contributing to prolonged life expectancy at birth, in cases of malignant neoplasms in Japan.

Tomoyuki Watanabe1, Masako Omori, Hiromi Fukuda, Hiroki Takada, Masaru Miyao, Yutaka Mizuno, Isao Ohsawa, Yuzo Sato, Toshihiko Hasegawa.   

Abstract

BACKGROUND: This study aimed to examine the contribution made by the change in mortality from malignant neoplasms to the life expectancy at birth, observed during the years 1965-1995 in Japan.
METHODS: We used data on the population and number of deaths by cause, age and sex in 1965, 1975, 1985 and 1995. The contribution of different ages and causes of death to the change in life expectancy were examined with the method developed by Pollard.
RESULTS: We found that, among all causes, the decrease of mortality from stomach cancer led to the greatest improvement in life expectancy for both sexes. On the other hand, negative contributions were seen with cancers of many sites, such as cancer of the intestine, liver and lung for males, and cancer of the intestine, gallbladder, lung and breast for females. Recently, the contributing years of all cancers have been negative because of the increase in mortality from malignant neoplasms. In addition, increase of death from malignant neoplasms in middle-aged and elderly people negatively influenced the life expectancy at birth.
CONCLUSIONS: Female cancer influenced the improvement in life expectancy at birth. Cancer for males, however, contributed little to improvement of life expectancy at birth except for a little prolongation of life expectancy at birth during the years 1965-1975. To develop a public health policy, the contributing years to life expectancy at birth can be a useful indication in evaluating the impact of death from various diseases. It is necessary to analyze the contribution made by various causes of death to the changes of life expectancy at birth.

Entities:  

Mesh:

Year:  2003        PMID: 12749605     DOI: 10.2188/jea.13.169

Source DB:  PubMed          Journal:  J Epidemiol        ISSN: 0917-5040            Impact factor:   3.211


  3 in total

1.  Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma.

Authors:  Hai-Gang Li; De-Rong Xie; Xi-Ming Shen; Hong-Hao Li; Hong Zeng; Yun-Jie Zeng
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

2.  Establishment and characterization of human hepatocellular carcinoma cell line FHCC-98.

Authors:  Chao-Yang Lou; Ying-Ming Feng; Ai-Rong Qian; Yu Li; Hao Tang; Peng Shang; Zhi-Nan Chen
Journal:  World J Gastroenterol       Date:  2004-05-15       Impact factor: 5.742

3.  Volume reduction surgery for advanced hepatocellular carcinoma.

Authors:  Kazuto Inoue; Takayuki Nakamura; Taira Kinoshita; Masaru Konishi; Toshio Nakagohri; Tatsuya Oda; Shinichiro Takahashi; Naoto Gotohda; Takayuki Hayashi; Shigeru Nawano
Journal:  J Cancer Res Clin Oncol       Date:  2004-03-18       Impact factor: 4.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.